To see the other types of publications on this topic, follow the link: Patentability criteria.
Journal articles on the topic 'Patentability criteria'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 23 journal articles for your research on the topic 'Patentability criteria.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Holopainen, Sami, Olli-Pekka Piirilä, and Antti Salmela. "Patentability of mathematical modelling and simulation methods." Rakenteiden Mekaniikka 52, no. 2 (July 12, 2019): 114–24. http://dx.doi.org/10.23998/rm.76251.
Full textAbstract:
"Patentability" refers to conditions laid down by law to what can be patented and what cannot. In this study, changes in the patentability of simulation methods are compared with the rapid development of computational science since 1970s. Although technological progress has caused computational simulation and modelling methods to grow to an everyday tool of technology, these methods have traditionally been excluded from patentability as "non-technical subject matter" or "abstract ideas". We describe the changes in patentability criteria in Europe and in the USA, and illustrate the development of patenting activity in this field during the last decade. Practisers should be aware of these changes, and investigate the possibilities they might offer.
2
Lazaridis, George, and Bruno van Pottelsberghe de la Potterie. "The rigour of EPO’s patentability criteria: An insight into the “induced withdrawals”." World Patent Information 29, no. 4 (December 2007): 317–26. http://dx.doi.org/10.1016/j.wpi.2007.05.001.
Full text
3
Sorte, Smita Rameshrao, and Sachin Babu Rathod. "Reliability and patentability of academic-rank promotional criteria in medical colleges of India." Journal of Bangladesh Society of Physiologist 13, no. 2 (December 26, 2018): 78–83. http://dx.doi.org/10.3329/jbsp.v13i2.39485.
Full textAbstract:
A promotion refers to the progress of an employee’s position or ranks in a hierarchical constitution with an increase in status, responsibilities, and salary. Academic rank Promotional criteria considered by the Medical Council of India (MCI) include educational qualifications, seniority according to years of teaching experience and numbers of Publications. There is gap between faculty role in medical college and expectation for promotion in India. Impractical expectation beyond the self-competency has promoted unethical practices. The various scientific misconduct problems had faded the quality of research in India. So the expected criteria for the evaluation of faculty members are needed to be re-adjusted by policymakers, according to the facilities of the scientific centers and human, social and economic resources at the institute. Medical Council of India needs to evolve and implement a suitable promotional policy for faculty members of medical colleges in India.
J Bangladesh Soc Physiol. 2018, December; 13(2): 78-83
4
Wu, Chi-Hua, and Ding-Bang Luh. "Positivity creation and its effect on idea patentability: a case of a new faucet invention." MATEC Web of Conferences 201 (2018): 04001. http://dx.doi.org/10.1051/matecconf/201820104001.
Full textAbstract:
Among criteria of patentability, concern of novelty is taking priority in comparing to non-obviousness and industrial applicability. However, novelty is difficult to be demonstrated before conducting a thorough research of the prior art after a proposal is been designed, which is time-consuming. Under such circumstance, 1) Positive creativity is applied in this research to enhance idea patentability by positively building it during a design process. 2) Start with elaborating idea of positive creativity, its conceptual tool is applied in this research to design a new faucet, and do actual patent application. 3) The result of patents obtained in several countries, including invention (Taiwan) and design patents (Taiwan, U.S., China), indicates that positive creativity is capable of producing patentable ideas. 4) Faucet manufacturing is a traditional industry within which theoretically more difficult to get invention patents. This further indicates that positive creativity (through positivity creation) should have similar effect in providing patentable ideas in highly-innovative industries.
5
Karbowski, Adam. "Controversies over the moral justification for patent protection in biotechnology." Annales. Etyka w Życiu Gospodarczym 21, no. 5 (March 22, 2018): 57–66. http://dx.doi.org/10.18778/1899-2226.21.5.05.
Full textAbstract:
This paper discusses the controversies over the moral justification for patent protection in biotechnology. Special emphasis has been put on the controversy over the moral justification for patent protection of stem cells. By referring to arguments for (1) human dignity and (2) patentability criteria, the moral justifiability of patent protection of stem cells is in serious doubt. A whole section of the paper is devoted to the moral issues linked to patent protection in biotechnology and their political and economic significance. An attempt is made to solve some of the discussed problems, i.e., the introduction of decision criteria based on the system of values shared by the members of a given society.
6
Belikova, Ksenia Michailovna. "Bioprinting and culture of tissues and organs in the BRICS countries (on the example of Brazil, India, China, and South Africa): approaches of legislation on intellectual property." Право и политика, no. 5 (May 2020): 35–57. http://dx.doi.org/10.7256/2454-0706.2020.5.32826.
Full textAbstract:
This article examines the legal regulation of bioprinting (3D printing) and culture of tissues and organs in the BRICS countries through the prism of protection of intellectual property. The work demonstrates the means of protection of results acquired at each stage of bioprinting by the norms of copyright and patent law, as well as touches on the questions of the need (possibility) for patenting of “bioprinters”, “bioinks”, “biopapers”, etc. The goal of this research is to determine the necessary and possible boundaries for patenting (copyright law protection) of the means, products, processes and their moral-ethical acceptance in the society. The novelty of this work consists in a comprehensive analysis of the approaches of BRICS countries towards development, legal formalization and protection of bioprinting and culture of tissues and organs as medical and non-medical technologies from the perspective of intellectual property law. The author attempts to answer the question of (non)patentability of the process (means) and result (product) of bioprinting of tissues and organs, the “bioprinters” themselves, as well as the “bioinks” and “biopapers” they use. With regards to (non)patentability of tissues and organs acquired through 3D printing, a conclusion is made that there is an unfavorable environment for their patenting, though their production, in the author’s opinion, should the right to patenting providing that they meet the criteria (other conditions) set by patenting law of a particular country.
7
Childs, Michelle. "Towards a Patent Pool for HIV Medicines: The Background." Open AIDS Journal 4, no. 1 (January 19, 2010): 33–36. http://dx.doi.org/10.2174/1874613601004020033.
Full textAbstract:
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as India now grant pharmaceutical product patents so competition between multiple manufacturers will not be able to play the role it has in bringing down the price of newer drugs. Overcoming these patent barriers will require a range of solutions, such as restricting patentability criteria, or compulsory licensing. One additional systematic solution is provided by the patent pool, a collective solution to the management of patent rights, initially presented by Médecins Sans Frontières to the French Foreign Ministry and subsequently the UNITAID Executive Board in 2006. A patent pool must not be implemented at any costs, but answer medical needs, be based on economic realities and meet the access needs of the developing world, including middle-income countries.
8
Barycki, Michał. "Disclaimers in European Patent Applications." GRUR International 69, no. 12 (October 16, 2020): 1204–16. http://dx.doi.org/10.1093/grurint/ikaa125.
Full textAbstract:
Abstract A European patent application may be amended by, among others, deleting a part of the claimed subject matter under established conditions or by the incorporation of an undisclosed or disclosed disclaimer. Disclaimers are a useful tool in order to maintain the balance between the practical needs of applicants and the interests of third parties in legal clarity and completeness. The incorporation of disclaimers may not extend beyond the content of the European patent application as filed and the protection it confers. The purpose of this paper is to illustrate how an applicant can introduce a negative technical feature into the patent application in the light of the extensive judicial practice of the Technical and Enlarged Boards of Appeal of the European Patent Office. The author has analysed the criteria for disclaimers set out in decisions G 1/03, G 2/10 and G 1/16 in accordance with the general notion of patent law and requirements of patentability. Additionally, this problem was also characterized in the light of the judicial practice of national courts and legislations of the EU Member States.
9
Gupta, Sonu, Ravinder Nath Bansal, Surender Pal Singh Sodhi, and Gursimrat Kaur Brar. "Evaluating Indian Professionals Knowledge for Innovation and Need for Patent Education." Utamax : Journal of Ultimate Research and Trends in Education 3, no. 2 (July 28, 2021): 68–79. http://dx.doi.org/10.31849/utamax.v3i2.6904.
Full textAbstract:
The Patent system encourages invention, disclosure, and investment. Several patents are granted in medical sciences, but a misconception remains with health care professionals regarding criteria for patentability of their valuable invention. Though the Indian Patent system has promoted the progress of science and technology, its scope has not been extended to treatment procedures in medical and dental sciences. This research was conducted to assess the knowledge and awareness of health care professionals about the Indian patent system. The study was conducted to assess the awareness and knowledge of the Indian patent system and the need for patent education among professionals of different streams. This cross-sectional study was carried out among private practitioners of different streams (medical and dental, ayurvedic, and homeopathic). Results made a poor show of patent education and knowledge. Only 6% of participants had more than 50% knowledge regarding this topic. Since educational institutions are opting for accreditations. Research and innovation is an important criterion for that. This study highlighted that there is a great need for patent education for professional and institutional growth.
10
Pavlyuk, Olha, Nataliia Parasiuk, Alona Dutko, Vasyl Parasiuk, and Oksana Stasiv. "Protection of patent law objects, created by artificial intelligence (AI) technologies." Revista Amazonia Investiga 10, no. 44 (September 29, 2021): 230–40. http://dx.doi.org/10.34069/ai/2021.44.08.22.
Full textAbstract:
The aim of the article is to solve the scientific problem of outlining the issue of protection of patent law objects created using artificial intelligence technologies, and to establish whether it is possible to recognize artificial intelligence technologies as inventor at the present stage of development of legal systems. Philosophical, comparative-legal and system-structural methods were used in the research process. Based on the analysis of the European Patent Convention, the main generally accepted conditions of patentability of the invention are determined: novelty, inventive step, industrial applicability. It has been established that inventions created by artificial intelligence technologies will meet such criteria provided that certain requirements are met. In the context of the study, the case of the invention of artificial intelligence «DABUS» is analyzed and the results of its consideration in the European Patent Organization, the United Kingdom and the United States are summarized. In particular, it has been established that artificial intelligence technologies are currently not considered as inventors in either the Romano-Germanic or Anglo-Saxon legal systems.
11
Ndlovu, Lonias. "Enhancing the Value of Patents as Corporate Assets in South Africa: How can Artificial Intelligence (AI) Assist?" Potchefstroom Electronic Law Journal 24 (June 23, 2021): 1–38. http://dx.doi.org/10.17159/1727-3781/2021/v24i0a10736.
Full textAbstract:
Although the accounting definition of assets contemplates intangible, abstract assets such as those embodied in intellectual property (IP), South African company law largely views IP as a legal and not a business asset. This paper tentatively suggests an approach that uses artificial intelligence (AI) to mitigate weaknesses in the South African patent law relating to the absence of patent searches and examinations. It is hoped that using AI will enable the filing of quality patents that satisfy the prescribed patentability criteria. High-quality patents will allow companies to accumulate patents as corporate assets. The approach is based on the algorithmic use of AI technologies such as machine learning, natural language processing, deep learning alongside the Internet of Things, and IP analytics to strengthen South Africa’s IP system and create asset value for corporations. The paper recommends using the proposed AI technologies by companies and the Patents Office to enable the filing of high-quality patents, which will lead to the accumulation of corporate assets in the form of patents. The methodology is doctrinal, and the paper relies on recent literature on IP and AI, South African law, case law and examples drawn from studies conducted in other countries.
12
Fedotova, Hanna, and Svitlana Fyl. "Protection of intellectual property rights in the field of biotechnology." Theory and Practice of Intellectual Property, no. 6 (December 27, 2021): 38–48. http://dx.doi.org/10.33731/62021.249001.
Full textAbstract:
Keywords: intellectual property rights, biotechnologies, patenting, legal protection,legislation
Current trends of globalization and the process of European integrationof Ukraine necessitate the creation of an effective mechanism of legal regulationof intellectual property rights in the field of biotechnology, due to the constitutionalprovisions according to which human life and health are the highest value inthe state. The purpose of the study was to determine the legal regulation of protection
of intellectual property rights in the field of biotechnology. Empirical and theoreticalmethods of scientific cognition are used for comprehensive consideration of the topicof the article. It has been found that modern biotechnological advances require inventorsnot only to secure monopoly rights to use them, but also to comply with the moraland ethical criteria for the perception of inventions created by genetic engineeringand living matter. It is determined that the legal system of intellectual property protectionin the field of biotechnology is based on the provisions of the Constitution ofUkraine, the Civil Code of Ukraine, regulations in the field of health and agriculture,international treaties and special legislation in the field of intellectual property. It isestablished that the system of legal protection of biotechnological inventions consistsof the acquisition of intellectual property rights to these inventions (establishment ofthe object of patenting and compliance with patentability, state registration of inventions)and the use and disposal of intellectual property rights to such inventions. Alegislative support of legal protection of biotechnological inventions is seen in furtherempirical research and theoretical and methodological substantiation in order to determinethe legal mechanisms of their practical implementation.
13
Alves de Lima, Araken, Patricia Carvalho dos Reis, Julio César Moreira Reis Castelo Branco, Rodrigo Danieli, Cibele Cristina Osawa, Eduardo Winter, and Douglas Alves Santos. "Scenario-Patent Protection Compared to Climate Change." International Journal of Social Ecology and Sustainable Development 4, no. 3 (July 2013): 61–70. http://dx.doi.org/10.4018/jsesd.2013070105.
Full textAbstract:
The United Nations Framework on Climate Change (UNFCCC) took effect as a treaty in 1994 to promote international cooperation in the fight against global warming. Currently, nearly 190 countries are signatories of the UNFCCC, which has had successive additions as the Kyoto Protocol (1997). In 1995, the Climate Technology Initiative was established within the UNFCCC to encourage international cooperation in the accelerated development and diffusion of environmentally Sound Technologies - EST. Such technologies are also capable of protection provided by patents, and this kind of protection is a valuable tool for the industrial production inventions to become a worthwhile investment, contributing to economic development. Many patent applications claim advantages relative to efficiency, waste reduction, or even the costs of operation/manufacturing. However, the difficulty of accurately distinguishing the EST’s technologies among others, which are those that only claim environmental benefits, compared to those who actually have a higher potential to promote a more positive impact on the environment directed. This study aims to report some performance initiatives in relations between technologies, focusing on the so-called “GREEN”, and the effects of climate change. Some initiatives have already been started in countries such as Australia, Canada, United States, United Kingdom, Spain, Japan, South Korea and Israel. These nations are constituted in the form of their industrial property offices, as entities that have implemented regulations regarding the patentability of requests for green technologies or EST’s such requests are known as “green patents” applications. In this context, it is highlighted that the definition of “green patents” differs from country to country and this leads to greater uncertainty in this designation, with the codes of the International Patent Classification (IPC) should be prioritized. This study observed that, in the case of South Korea, green patents are technologies classified in accordance with the interests of the Government, or, according to designations of environmental laws. Moreover, it still shows that South Korea, Australia, United States, Japan, Israel already have programs to promote accelerated examination of “green patents” applications with different criteria.
14
Mishra, Umakant. "Patentability Criteria in Different Countries." SSRN Electronic Journal, 2014. http://dx.doi.org/10.2139/ssrn.2430768.
Full text
15
Singh, Manisha. "Non Obviousness as the Criteria for Patentability." SSRN Electronic Journal, 2013. http://dx.doi.org/10.2139/ssrn.2214513.
Full text
16
Abhinav, Shrivastava. "Doctrine of Inherent Anticipation Under Patentability Criteria." SSRN Electronic Journal, 2011. http://dx.doi.org/10.2139/ssrn.1971168.
Full text
17
Devarapalli, Pratap, Nishad Deshpande, and Rajkumar Hirwani. "Patenting Bioinformatic Inventions: Global Perspective." Journal of Commercial Biotechnology 24, no. 2 (August 27, 2018). http://dx.doi.org/10.5912/jcb831.
Full textAbstract:
Patenting bioinformatic inventions has become a ride on the rail to the scientists and inventors. Specifically in bioinformatics, drafting an invention in bounds of patentability criteria is one the most critical task for an inventor to protect his invention. As bioinformatics is a budding field of science, patentable subject matter in bioinformatics was not specifically defined by most of the patent offices in the world. In this regard, we have tried to explain patentable subject matter in bioinformatics by classifying bioinformatics into different subject fields. Additionally, we have tried to trace out patentable subject matter for bioinformatic inventions based on country-specific patentability standards and granted bioinformatic patents of US, Europe, India, Canada and Australia.
18
Manchikanti, Padmavati. "Writing successful patents and overcoming patent barriers." Indian Journal of Genetics and Plant Breeding (The) 79, no. 01S (January 16, 2019). http://dx.doi.org/10.31742/ijgpb.79s.1.30.
Full textAbstract:
Inventions related to pre-harvest and post-harvest technologies have revolutionized agriculture. There is a significant growth of intellectual property rights (IPR) in agriculture across the globe. The predominant forms of IP relevant to agriculture sector are patents and designs. Patents are given to inventions that qualify patent eligibility, patentability criteria and disclosure norms. In the area of agriculture, patents provide a great opportunity for improving agricultural processes and products. Understanding the requirements of an invention under the Indian Patents Act, 1970 is necessary to know what can be patentable in India. The criteria of novelty, non-obviousness and industrial application and disclosure norms are applicable to all inventions irrespective of the technology areas. Examination guidelines for each technology area indicate to the elaborateness of the practice in relation to patents. While preparing patent specifications for agriculture inventions, it is important to ensure that the subject matter claimed should not be a method of agriculture (under Section 3h) or plants or plant parts (under Section 3j of the Act). Identification of relevant prior art and its anticipatory value is very important for the assessment of novelty of inventions. Agriculture inventions which can lower the cost, be obtained by reduced number of steps and are environment friendly can be considered under ‘economic significance’ by the Indian patent office (under the purview of Section 2(1) ja). Adhering to the disclosure norms (as mandated under Section 10 of the Act) are also important. Inventors/applicants need to also consider the deposit requirements. The present work examines the relevance of IPR and expansion of the patentability criteria, disclosure norms and additional requirements in relation to agriculture. It will highlight the need for patent search as an integral requirement for research, the process of preparation of invention disclosures to enhance the innovative ability of academic institutions as well as researchers.
19
Raju, Dr K. D. "The Debacle of Novartis Patent Case in India: Strict Interpretation of Patentability Criteria Under Article 27 of the Trips Agreement." SSRN Electronic Journal, 2007. http://dx.doi.org/10.2139/ssrn.1030963.
Full text
20
Юрій Капіца. "UTILITY MODEL PROTECTION - TRENDS IN THE EUROPEAN UNION AND CHALLENGES FOR UKRAINE." Theory and Practice of Intellectual Property, no. 3 (June 30, 2020). http://dx.doi.org/10.33731/32020.216554.
Full textAbstract:
The issue of utility model (UM) protection in Ukraine in1993–2020 and the practice of the EU Member–States is considered. It is noted theproblem of UM trolling and exceeding the number of applications in Ukraine for UM in comparison with inventions. It is associated with the expansion in 2003 of the UM object in addition to the device also to a process, substance, microorganism strain, plant or animal cells culture and limiting the criterion of patentability only to the requirementnovelty and industrial applicability.It is concluded that the adoption of the Law of 21.07.2020 № 816-IX is an important step to limit patent trolling. The Law provides for exclusion from the protection of the substance and the introduction of post grant opposition in the Appellate Chamber.However the Law does not solve the problem of patent trolling at the customs border and did not exclude process from the protection. Also there will still be the problem at the courts as well Appellate Chamber to declare a utility model invalid if the UM is a new but obvious technical solution due to the lack of inventive step requirement or lower requirements for inventive step.The peculiarities of the protection of the utility model in the 15 old EU member states and the United Kingdom are analyzed. It is shown the tendency to increase level of protection of UM in the EU. In 6 EU countries there is no UM protection. In 5 there is an inventive step requirement. In 2 countries protection is possible only for three-dimensional objects (Italy, Greece). In 2 countries (Finland, Spain) - lower requirements for the inventive step.The directions of change of UM legislation in Ukraine are substantiated, including: Option 1: cancellation of protection of UM taking into account experience of Luxembourg, Sweden, Great Britain, Belgium, the Netherlands.Option 2: introduction of protection only for three-dimensional UM (protection is not provided to the method, substances, biotechnological inventions). Establishment of the criterion of inventive step the same as for inventions. Determination of mandatory examination of compliancewith the criteria of patentability (novelty, inventive step, industrial applicability) before the enforcement of UM in the courts, customs, Antimonopoly Committee.Option 3. Definition of protection of utility model as a form of protection of the invention with similar requirements as in option 2.
21
V., LITVINOVA ELENA, POSILKINA OLGA V., and MASLOVA NATALIIA F. "SOFOSBUVIR: TREATMENT OF CHRONIC HEPATITIS C AND THE MAIN TRENDS IN PATENT PROTECTION." International Journal of Applied Pharmaceutics, May 24, 2019, 8–14. http://dx.doi.org/10.22159/ijap.2019v11i4.33502.
Full textAbstract:
The purpose of the study was to analyze and systematize the literature data on the benefit/risk ratio of sofosbuvir administration in the treatment of patients with chronic hepatitis C and the main trends in its patent protection. Studies were conducted using databases on the Internet: Ukrainian patent office, the European patent office, the US patent office, the Food and drug administration, European Medicines Agency (EMEA), State enterprise “The State Expert Center” of the Ministry of Health of Ukraine. It has used retrospective, logical, systematic and analytical methods. Data from clinical studies abroad and meta-analyses indicate that sofosbuvir is one of the most promising drugs for the treatment of chronic HCV infection. Its indisputable advantages are that this drug can be used with different genotypes of the virus, decompensated liver function, it is well tolerated. Sofosbuvir has an improved safety profile and a low probability of viral resistance. The high cost of sofosbuvir is due to the powerful patent protection. As mechanisms for working with patent barriers, it is recommended to use the flexible mechanisms of the TRIPS Agreement: the grant of compulsory licenses, the implementation of parallel imports, the tightening of the criteria for patentability (prohibition of patenting new forms that do not improve therapeutic efficacy).
22
Vazhathodi, Muhammed Faris. "A Study on Patentability of Nanotechnology Inventions at the European Patent Organisation Based on Decisions by the Examination Division, the Opposition Division and the Technical Board of Appeal." GRUR International, February 24, 2022. http://dx.doi.org/10.1093/grurint/ikac003.
Full textAbstract:
Abstract The World Intellectual Property Organisation (WIPO) has identified nanotechnology as one of the prominent technologies of recent times (WIPO Magazine ‒ August 2011). Nanotechnology has a wide variety of applications in the field of medicine which are leading to the evolution of a new branch of medical science – nanomedicine. This involves using particles or materials within the size range of one nanometre and a thousand nanometres to diagnose, treat, and prevent various diseases. Biomedical nanotechnology, bionanotechnology, and nanomedicines are applications of nanotechnology in medicine and this article covers these three areas under the umbrella-term ‘nanomedicines.’ The European Union is a significant player in the wider nanotechnology market (including nanomedicines). At the European Patent Office (EPO), the number of nanotechnology patent applications (including nanomedicines) is increasing every year. The European Patent Convention (EPC) – the unified European patent system – came into existence in 1973. It provided patent protection for valid technologies according to the patentability criteria provided by EPC, and Art. 27(1) of TRIPS directs its signatories to offer patent protection for every technology equally. However, nanotechnology’s unique nature poses a threat to the existing patent law. This paper critically analyses certain decisions by the EPO and its Boards of Appeal considering the technological speciality of nanotechnology inventions with reference to nanomedicines.
23
Singh, Neeraj, Shweta Rai, and Sankha Bhattacharya. "A Conceptual Analysis of solid Self-emulsifying drug Delivery System and its Associate Patents for the Treatment of Cancer." Recent Patents on Nanotechnology 14 (September 9, 2020). http://dx.doi.org/10.2174/1872210514666200909155516.
Full textAbstract:
Background: About two-third of new drugs reveal low solubility in water due to that; it becomes difficult for formulation scientists to develop oral solid dosage forms with a pharmaceutically acceptable range of therapeutic activity. In such cases, S-SMEEDS are the best carrier used universally for the delivery of hydrophobic drugs. SEDDS were also used, but due to its limitations, S-SMEDDS used widely. These are the isotropic mixtures of oils, co-solvents, and surfactants. S-SMEDDS are physically stable, easy to manufacture, easy to fill in gelatin capsules as well as improves the drug bioavailability by releasing the drug in the emulsion form to the gastrointestinal tract and make smooth absorption of the drug through the intestinal lymphatic pathway. Methods: We took on the various literature search related to our review, including the peer-reviewed research, and provided a conceptual framework to that. Standard tools are used for making the figures of the paper, and various search engines are used for the literature exploration.In this review article the author discussed the importance of S-SMEDDS, selection criteria for excipients, pseudo-ternary diagram, mechanism of action of S-SMEDDS, solidification techniques used for S-SMEDDS, Characterization of SEDDS and S-SMEDDS including Stability Evaluation of both and future prospect concluded through recent findings on S-SMEDDS on Cancer as well as a neoteric patent on S-SMEDDS Results: Many research papers discussed in this review article, from which it was found that the ternary phase diagram is the most crucial part of developing the SMEDDS. From the various research findings, it was found that the excipient selection is the essential step which decides the strong therapeutic effect of the formulation. The significant outcome related to solid-SMEDDS is less the globule size, higher would be the bioavailability. The adsorption of a solid carrier method is the most widely used method for the preparation of solid-SMEDDS. After review of many patents, it is observed that the solid-SMEDDS have a strong potential for targeting and treatment of a different type of Cancer due to their property to enhance permeation and increased bioavailability. Conclusion: S-SMEEDS are more acceptable pharmaceutically as compare to SEDDS due to various advantages over SEDDS viz stability issue is prevalent with SEDDS. A number of researchers had formulated S-SMEDDS of poorly soluble drugs and founded S-SMEDDS as prospective for the delivery of hydrophobic drugs for the treatment of Cancer. S-SMEEDS are grabbing attention, and the patentability on S-SMEDDS is unavoidable, these prove that S-SMEEDS are widely accepted carriers. These are used universally for the delivery of the hydrophilic drugs and anticancer drugs as it releases the drug to the gastrointestinal tract and enhances the systemic absorption. Abstract: Majority of active pharmaceutical ingredients (API) shows poor aqueous solubility, due to that drug delivery of the API to the systemic circulation becomes difficult as it has low bioavailability. The bioavailability of the hydrophobic drugs can be improved by the Self-emulsifying drug delivery system (SEDDS) but due to its various limitations, solid self-micro emulsifying drug delivery systems (S-SMEDDS) are used due to its advantages over SEDDS. S-SMEDDS plays a vital role in improving the low bioavailability of poorly aqueous soluble drugs. Hydrophobic drugs can be easily loaded in these systems and release the drug to the gastrointestinal tract in the form of fine emulsion results to In-situ solubilisation of the drug. In this review article the author's gives an overview of the solid SMEDSS along with the solidification techniques and an update on recent research and patents filled for Solid SMEDDS.